The present results indicate that FGF-21 may be a biologically relevant substrate for FAP in humans, but not in mice and therefore, that FAP inhibitors may prove useful in the treatment of diabetes and metabolic disorders in humans by increasing the lifetime of FGF-21. This evidence concerns the gene FGF21 and Other metabolic disease.